JP2017531699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531699A5 JP2017531699A5 JP2017540976A JP2017540976A JP2017531699A5 JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5 JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- hpv
- use according
- vaccine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002566 papillomavirus vaccine Drugs 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 201000011510 cancer Diseases 0.000 claims 19
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 230000003902 lesion Effects 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940047091 other immunostimulants in atc Drugs 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 229940124551 recombinant vaccine Drugs 0.000 claims 4
- 201000010153 skin papilloma Diseases 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 3
- 208000000260 Warts Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000007857 degradation product Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 | |
| US62/068,332 | 2014-10-24 | ||
| PCT/US2015/057150 WO2016065281A1 (en) | 2014-10-24 | 2015-10-23 | Cancer and skin lesion treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531699A JP2017531699A (ja) | 2017-10-26 |
| JP2017531699A5 true JP2017531699A5 (enExample) | 2018-11-15 |
| JP6663438B2 JP6663438B2 (ja) | 2020-03-11 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540976A Active JP6663438B2 (ja) | 2014-10-24 | 2015-10-23 | 癌および皮膚病変の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (enExample) |
| EP (1) | EP3209676A4 (enExample) |
| JP (1) | JP6663438B2 (enExample) |
| KR (1) | KR102285401B1 (enExample) |
| CN (1) | CN107001430A (enExample) |
| AU (1) | AU2015335652B2 (enExample) |
| BR (1) | BR112017008280A2 (enExample) |
| CA (1) | CA2965498A1 (enExample) |
| CL (1) | CL2017001008A1 (enExample) |
| IL (1) | IL251825B2 (enExample) |
| MX (1) | MX395186B (enExample) |
| MY (1) | MY195018A (enExample) |
| PH (1) | PH12017500754A1 (enExample) |
| SG (1) | SG11201703262UA (enExample) |
| WO (1) | WO2016065281A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019506435A (ja) * | 2016-02-27 | 2019-03-07 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60126737T2 (de) * | 2001-03-23 | 2007-11-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| TWI349557B (en) | 2002-12-20 | 2011-10-01 | Glaxosmithkline Biolog Sa | Use of hpv 16 and hpv 18 vlps for vaccine preparation |
| PE20060434A1 (es) * | 2004-06-16 | 2006-06-08 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| CN101622008A (zh) * | 2007-03-09 | 2010-01-06 | 默克公司 | 乳头瘤病毒疫苗组合物 |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| EP2416798B1 (en) * | 2009-04-10 | 2017-09-20 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| US9724404B2 (en) * | 2009-04-13 | 2017-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | HPV particles and uses thereof |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| US9566323B2 (en) | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| BRPI1014718A2 (pt) * | 2009-06-25 | 2016-04-12 | Glaxonsmithkline Biolog S A | polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| CA2838387A1 (en) * | 2011-06-06 | 2012-12-13 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| BR112014023092A8 (pt) * | 2012-03-18 | 2017-07-25 | Glaxosmithkline Biologicals Sa | Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit |
| WO2013149017A1 (en) * | 2012-03-28 | 2013-10-03 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9974849B2 (en) | 2013-10-13 | 2018-05-22 | Bioventures, Llc | Human Papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
-
2017
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2848064T3 (es) | Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas | |
| Wu et al. | Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation | |
| JP2015533376A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| JP2010530362A5 (enExample) | ||
| Tran et al. | Spontaneous regression of metastatic melanoma after inoculation with tetanus–diphtheria–pertussis vaccine | |
| SA521421371B1 (ar) | لقاحات الببتيد | |
| Devaraja | Current prospects of molecular therapeutics in head and neck squamous cell carcinoma | |
| Suckow | Cancer vaccines: harnessing the potential of anti-tumor immunity | |
| Ding et al. | Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer | |
| JP2018509423A5 (enExample) | ||
| JP7460094B2 (ja) | 子宮頸がんの治療方法 | |
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| Palladini et al. | Cancer immunoprevention: from mice to early clinical trials | |
| JP2017531699A5 (enExample) | ||
| JP6663438B2 (ja) | 癌および皮膚病変の治療 | |
| EP4196157A1 (en) | Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment | |
| Granadillo et al. | LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs | |
| RU2832963C2 (ru) | Способ лечения рака шейки матки | |
| HK1241898A1 (en) | Cancer and skin lesion treatment | |
| Kumar et al. | The Current Landscape for Human Papillomavirus Vaccination in Oropharyngeal Carcinoma | |
| Draganov et al. | 290 Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells | |
| Melief | Peptide-based therapeutic cancer vaccines | |
| Alfonso et al. | Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16 | |
| Elliott | Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9) |